Shanghai Fosun Pharmaceutical (Group) Co (HK:2196) has released an update.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has announced the acceptance of their subsidiary’s new drug registration application by the National Medical Products Administration. The drug, Norepinephrine Bitartrate Injection, is designed to treat severe and acute hypotension in adults and represents a RMB3.82 million investment in research and development by the group. This marks a significant milestone for the company as it continues to expand its pharmaceutical offerings.
For further insights into HK:2196 stock, check out TipRanks’ Stock Analysis page.
